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MT1-MMP is the critical determinant of matrix degradation and
invasion by ovarian cancer cells
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Membrane-type 1 matrix metalloproteinase (MT1-MMP), a transmembrane metalloprotease that plays an important role in the
invasion of many solid tumour types, promotes pericellular matrix degradation and may also stimulate tumour cell motility. As both
these processes are key contributors to intraperitoneal ovarian tumour metastasis, we examined six ovarian cancer cell lines to
determine whether MT1 is a critical mediator of invasive behaviour for this tumour type. Our results indicated that only those cell
lines that expressed MT1 were capable of penetrating a type I collagen barrier, with the capacity for both matrix degradation and
invasion reflecting endogenous MT1 expression level. Ectopic MT1 expression endowed an invasive phenotype upon cell lines lacking
MT1 that were previously non-invasive, indicating the crucial role of this protease. Conversely, invasion was abolished by tissue
inhibitor of metalloproteinase-2 (TIMP-2), a potent inhibitor of MT1, yet was minimally affected when other (secreted) MMPs were
inhibited using TIMP-1 and the gelatinase inhibitor SB-3CT. Whereas collagen I degradation was strikingly accelerated by ectopic MT1
expression, cell motility remained unchanged. We conclude that MT1 is necessary for collagen I invasion by ovarian cancer cells, and
that its requisite activity is the promotion of matrix degradation, with no impact on cell motility.
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Epithelial ovarian cancer is a highly aggressive malignancy
associated with a poor prognosis. These tumours have usually
metastasised before clinical presentation, and fewer than 30% of
patients diagnosed with metastatic disease survive beyond 5 years
(Landis et al, 1999), as present therapeutic strategies are ultimately
ineffective in preventing disease progression. In contrast to most
other solid tumours, which metastasise through a multi-step
haematological route, ovarian cancer cells metastasise via exfolia-
tion from the primary tumour into the peritoneal cavity. Ovarian
cancer cells preferentially bind collagen I and this ligand is highly
effective in stimulating motility in these cells (Moser et al, 1996;
Burleson et al, 2004). Indeed, during peritoneal metastasis, tumour
cells attach preferentially at locations where the mesothelium is
disrupted and the underlying collagen I-rich stromal matrix is
exposed (Ghosh et al, 2002; Mochizuki et al, 2004).
Metastatic cancer cells have acquired the proteolytic mechan-
isms required for penetration of basement membrane and collagen
I-rich stromal matrices, which are normally refractory to invasion
by epithelial cells (Sivridis et al, 2004). Matrix metalloproteases
(MMPs), key mediators of ECM degradation (Egeblad and Werb,
2002), are upregulated in invasive cancers including those of
ovarian origin (Ghosh et al, 2002). Although the importance of
MMPs in ovarian cancer metastasis is recognised (Stack et al, 1998;
Ghosh et al, 2002), clinical trials that have evaluated the broad-
range MMP inhibitors marimastat and tanomastat for cancer
treatment, including ovarian, have yielded disappointing results
(Coussens et al, 2002; Hirte et al, 2006). This may be partially
attributed to the concomitant inhibition of critical physiological
processes involved in combating tumour progression (Overall and
Lopez-Otin, 2002). It is therefore necessary to identify which
subsets of MMPs play a critical role in ovarian cancer metastasis,
so that they can be specifically targeted. A central role for a
transmembrane member of the MMP family, membrane-type 1
MMP (MT1), in cancer metastasis has emerged in association with
the aggressive behaviour of several cancer types (Aznavoorian
et al, 2001; Seiki, 2003; Ueda et al, 2003; Sabeh et al, 2004; Cao et al,
2005), as reviewed by Sounni and Noel (2005). We therefore sought
to determine whether this protease plays an essential role in
regulating ovarian cancer cell invasive behaviour.
The potency of MT1 owes to the ability of its proteolytic activity
to be focused, via its translocation to the leading edge of invasive
cancer cells (Mori et al, 2002). Indeed, MT1 is an essential
functional component of invadopodia (Chen and Wang, 1999;
Artym et al, 2006). Although MT1 is known for its potent
collagenolytic activity, it cleaves a range of additional ECM
substrates and cell surface-associated receptors. Membrane-type
1 MMP also activates soluble MMPs including pro-MMP-2, a
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sgelatinase that cooperates with MT1, to degrade stromal and
basement membrane barriers (Ohuchi et al, 1997; Seiki, 2003). The
resulting proteolysed matrix, in turn, promotes further tumour
growth and invasion (Hornebeck and Maquart, 2003).
Although matrix degradation is an obligatory aspect of tumour
cell invasion, cell motility is an additional important contributor.
Membrane-type 1 MMP has been implicated in enhancing cell
motility through cleavage of cell surface receptors, such as CD44
and syndecan-1, and through generation of haptotactic signals by
cleavage of laminin and collagen IV (Gingras et al, 2001; Rozanov
et al, 2001; Ueda et al, 2003; Takino et al, 2004). Consistent with
these observations, MT1 overexpression in some cancer cell types
appears to promote motility on collagen I and fibronectin
matrices, although the requirement for its enzymatic activity in
this process is controversial (Giannelli and Antonaci, 2000; Kajita
et al, 2001; Endo et al, 2003; Hornebeck and Maquart, 2003;
Koshikawa et al, 2005; cf. Cao et al, 2004). Collectively, these
studies suggest that MT1 may coordinate two cell activities
necessary for invasion – matrix degradation and cell motility.
Although the functionality of MT1 in many solid tissue cancers
is well established, information on its role in ovarian cancer is
limited. Membrane-type 1 expression by cells of orthotopically
implanted human ovarian cancer biopsies has been linked to a
more aggressive tumorigenicity (Drew et al, 2004), and inhibition
of MT1 activity has been shown to block collagen invasion in one
ovarian cancer cell line, DOV-13 (Ellerbroek et al, 1999; Ellerbroek
et al, 2001). However, as different ovarian cancer cell lines display
varying capacities for peritoneal tumour formation in vivo (Shaw
et al, 2004), and may use different mechanisms for invasion, we
sought to determine whether MT1 expression determines invasive
behaviour within a diverse panel of human ovarian cancer cell
lines. A polymerised collagen I matrix was used to assess invasion
for several reasons: Collagen I plays a key involvement in ovarian
cancer metastasis, being the most abundant matrix molecule in the
submesothelial stroma, and is the preferred substrate for ovarian
cancer cell attachment during peritoneal metastasis (Moser et al,
1996). Furthermore, the common use of Matrigel for invasion
assays has been brought into question as it does not form a
protease-dependent barrier and therefore does not adequately
represent a basement membrane (Hotary et al, 2006).
Although motility is an important aspect of ovarian cancer
peritoneal dissemination, the potential promotion of motility by
MT1 in ovarian cancer cells has not been assessed. Therefore, the
impact of MT1 expression on motility, in addition to collagen I
degradation, was evaluated. As elevated E-cadherin is known to
suppress invasive behaviour of cancer cells and to negatively
regulate MMP expression, including that of MT1 (Ara et al, 2000;
Takahashi et al, 2002; Nawrocki-Raby et al, 2003a,b; Hazan et al,
2004; Hlubek et al, 2004; Munshi and Stack, 2006), we also assessed
cadherin expression in these cell lines.
Our results demonstrate that MT1 activity is the prime
determinant of ovarian cancer cell invasion through a collagen I
matrix, and that this effect occurs through enhancement of matrix
degradation without impacting cell motility.
MATERIALS AND METHODS
Cell culture
Human ovarian cancer cell lines HEY, SKOV-3 and HOC-7 (obtained
from Dr Alexander Marks, University of Toronto, Toronto, ON,
Canada), OVCA429 (from Dr Robert Kerbel, Sunnybrook Hospital,
Toronto, ON, Canada), OVCAR-3 and ES-2 (from American Type
Culture Collection, Manassas, VA, USA) were maintained in
a-minimal essential media (a-MEM; GIBCO, Invitrogen Corp.,
Mississauga, ON, Canada) supplemented with 10% foetal bovine
serum (FBS; Cansera International Inc., Etobicoke, ON, Canada),
0.017% penicillin G and 0.01% gentamycin at 371C and 5% CO2.
RT–PCR
RNA was extracted from confluent cells grown on collagen I films
using an RNeasy mini kit (Qiagen, Mississauga, ON, Canada) and
reverse transcribed using a First Strand cDNA Synthesis Kit
(Invitrogen Corp.). Primers for MT1 were: forward 50-atcaa-
cactgcctacgagag-30 and reverse 50-aagacttcatcgctgcccat-30 (310bp
amplicon). Primers for E-cadherin were: forward 50-tccatttcttggtc-
tacgcc-30 and reverse 50-caccttcagccaacctgttt-30 (361bp amplicon).
Primers for RPL13a, used as an endogenous control gene (Mogal
A, 2006) were: forward 50-catcgtggctaaacaggtactg-30 and reverse
50-gcacgaccttgagggc-agcc-30 (319bp amplicon). An annealing
temperature of 59
oC was used for all primers. Samples were taken
at various cycles to ensure comparisons were made during the log
phase of amplification. For MT1, 26–30 cycles were used; for
RPL13a, 26 cycles and for E-cadherin 32 cycles. Real-time PCR for
MT1 was performed using the TaqMans Gene Expression Assay
system (Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions, using validated probes human
MT1 (no. 4331182) and eucaryotic 18S endogenous control (no.
4319413E).
Western blotting
Confluent cells were lysed in 50mM Tris-HCl, 120mM NaCl, 0.5%
NP-40, pH 7.4, containing protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). Total protein was quantified by
the Bio-Rad Protein Assay (Bio-Rad Laboratories, Mississauga,
ON, USA). Equal amounts of protein (10–20mg) were separated
by 12% SDS–PAGE and transferred onto PVDF membranes
(Amersham Biosciences, Oakville, ON, Canada), which were
probed for MT1 (1:1000, Ab815; Chemicon International Inc.,
Temecula, CA, USA), E-cadherin (1:1000, Chemicon), N-cadherin
(1:2500, Signal Transduction Laboratories, Lexington, KY,
USA) or b-tubulin (1:2000, T5168, Sigma-Aldrich). Secondary
HRP-coupled antibodies (Amersham, Oakville, ON, Canada)
were diluted 1:3000. Immunoreactive proteins were visualised
using ECL Western Blotting Detection Reagents (Amersham
Biosciences).
Gelatin zymography
Capacity for pro-MMP-2 activation was evaluated as a means of
assessing MT1 activity. This assay was performed using cells
seeded on 3D collagen I gels as is necessary for stimulation of
this event (Ellerbroek et al, 1999; Ellerbroek et al, 2001; Zigrino
et al, 2001). Vitrogent (eight volumes of 3mgml
 1) was
diluted with 1 volume of 10  aMEM and one volume of 0.1 M
NaOH, and the neutralised collagen I solution was polymerised
at 371C for 1h (100mlwell
 1; 48-well plate). Cells (1 10
5) were
seeded atop the collagen I gels in 300ml media that had been
pre-conditioned for 24h by human gingival fibroblasts (HGF), in
order to provide an exogenous source of pro-MMP-2 and tissue
inhibitor of metalloproteinase-2 (TIMP-2). Additional aliquots
of cells were seeded into wells for later quantification, to verify
equal cell numbers had been present during the assay, allowing
a meaningful comparison of pro-MMP-2 activation in the
conditioned media between the ovarian cancer cell lines. Following
a 36-h incubation, media was collected, diluted in non-reducing
sample buffer, and 20ml aliquots were separated by 12% SDS–
PAGE using gels co-polymerised with 0.016% gelatin (Sigma-
Aldrich). Gels were washed twice for 10min in 2.5% Triton X-100,
rinsed in dH2O, and incubated in enzyme activation buffer (50mM
Tris-HCl, pH 7.4, containing 0.2 M NaCl, 5mM CaCl2, and 0.166%
Brij 35) for 24–48h at room temperature. Coomassie blue (0.5%)
staining revealed proteins with gelatinolytic activity (gelatin
clearance).
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Experiments were conducted in 8mm transwell chambers (Costar,
Corning Inc., Corning, NY, USA). Vitrogent (Cohesion, Palo Alto,
CA, USA) was diluted in ice-cold PBS and neutralised with 0.01 N
NaOH for a final concentration of 0.2mgml
 1, of which 100ml was
applied to each transwell membrane, polymerised by incubation at
371C for 1h, and dried to form a compact collagen I film on the
membrane. The coated membranes were rinsed with PBS and
equilibrated in serum-free a-MEM using pre-warmed solutions.
Cells were resuspended in a-MEM containing 1% FBS, and 1 10
5
cells in 100ml were seeded into the upper wells. a-MEM (500ml)
supplemented with 10% FBS was used as a chemoattractant in the
lower well. Where applicable, the MMP inhibitor GM6001
(Chemicon) was added at 25mM, and TIMP-1 and TIMP-2
(obtained from Dr Chris Overall, University of British Colombia,
Vancouver, BC, Canada) were used at 2.5mg/ml. SB-3CT
(MMP2/MMP-9 inhibitor IV, Chemicon), which selectively
inhibits the gelatinases MMP-2 and MMP-9 (Kleifeld et al, 2001)
was used at 6mM. At the time of harvest (24–72h), invaded
cells were released from the bottom of the transwell insert using
500ml of 0.08% trypsin (in a 24-well plate), collected by
centrifugation, and invaded cells were quantified based on
nucleic acid content using CyQUANTt (Molecular Probes Inc.
Eugene, OR, USA) according to the manufacturer’s instructions.
Invasion experiments were performed three times, with data
normalised to HEY cell invasion levels and combined for the three
experiments.
Collagen I degradation
Chamber slides were coated with Vitrogent that had been
neutralised with 0.01 M NaOH and diluted in PBS such that
200ml containing 20mg collagen I were added to each well. The
collagen was subsequently polymerised at 371C for 1h and dried
down overnight to create compact collagen I films. Transwells were
coated with collagen as described above for transwell invasion. The
collagen matrices were biotinylated under sterile conditions, using
20mg/ml EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce, Rockford, IL,
USA) in 50mM sodium bicarbonate pH8.3 for 2h, quenched using
50mM Tris, pH7.5, and washed before addition of cells. For
examination of pericellular collagen degradation, cells were seeded
into chamber slide wells at low density (1 10
3cellswell
 1)i n
a-MEM containing 5% FBS. To assess collagen removal from
transwell pores, cells were seeded in transwell chambers as
described above for transwell invasion. Following incubation for
18–72h, matrix degradation experiments were terminated by
fixation in 4% paraformaldehyde, permeabilised with 0.1% Triton
X-100/PBS, blocked in 2% BSA/PBS, and stained with streptavidin-
Alexafluor-488 and rhodamine-phalloidin (Molecular Probes Inc.),
each diluted 1:200 in 2% BSA/PBS, then visualised by confocal
laser scanning microscopy (LSM 510, Carl Zeiss Inc., Toronto, ON,
Canada).
Ectopic MT1 expression
Membrane-type 1 expression constructs encoding wild-type flag-
tagged MT1 (MT1f) and catalytically inactive MT1 (MT1f-E240A)
(Tam et al, 2002), generated by the lab of Dr M Sharon Stack (Wu
et al, 2004), were obtained from Dr C Overall. Cells were
transfected using Fugene-HD (Roche Applied Science, Laval, PQ,
Canada) according to the manufacturer’s instructions. Additional
control cells were transfected with pEGFP (Clontech, Mountain
View, CA, USA) or left untransfected. Cells were seeded for
migration, collagen degradation, or invasion assays 24–36h post-
transfection.
Cell migration
Cell migration on collagen was assessed using transwell mem-
branes coated with unpolymerised collagen I (Vitrogent)a s
described for the invasion assay, except the collagen I was neither
neutralised nor incubated at 371C before being dried onto the
membrane. Cell seeding, application of chemoattractant, and
quantification of migrated cells were performed as described for
the transwell invasion assay, and experiments were terminated at
8–10h. As with the invasion assays, the migration assays were
initiated 24–48h post-transfection (where applicable) to allow for
cell recovery and ectopic expression of MT1. Migration experi-
ments were repeated three times.
RESULTS
Characterisation of MT1 expression and activity
Four of the six ovarian cancer cell lines examined, HEY, OVCA429,
ES-2, and HOC-7, expressed MT1 as determined both by real-time
PCR (Figure 1A) and Western blotting (Figure 1B). HEY cells
expressed the highest levels of MT1, whereas expression was not
detected in either the SKOV-3 or OVCAR-3 cells. To further
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Figure 1 Membrane-type 1-MMP expression in ovarian cancer cell lines.
(A) Real-time PCR results for MT1 expression by ovarian cancer cell lines
grown on a collagen I film. Results of RT–PCR for MT1 are depicted below,
with amplification of the endogenous control gene RPL13a shown to
confirm the use of equal template in all reactions. (B) Western blot with
polyclonal antibody Ab815 showing detection of MT1 expression in lysates
of cells grown on a collagen I film. The blot was re-probed for b-tubulin to
verify equal loading. (C) Gelatin zymography for pro-MMP-2 activation by
cells grown on a 3D collagen I gel and incubated with HGF-conditioned
media as an exogenous source of pro-MMP-2. Levels of pro-MMP-2
provided in the HGF-conditioned media are shown in the CTRL lane
(in absence of cells).
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based on the capacity of MT1 to cleave and activate pro-MMP-2
was performed (Ellerbroek et al, 1999; Ellerbroek et al, 2001;
Zigrino et al, 2001). The activation of pro-MMP-2 involves binding
of a TIMP-2/pro-MMP-2 dimer to MT1, presenting the pro-MMP-2
to a second MT1 molecule, which cleaves the pro-domain from
MMP-2 (Strongin et al, 1995). The pro-MMP-2 activation results
paralleled the MT1 expression pattern; only the cell lines that
expressed MT1 (HEY, OVCA429, ES-2, and HOC-7) were able to
cleave pro-MMP-2, with HEY demonstrating the most extensive
activity (Figure 1C).
Transwell collagen I invasion and matrix degradation
correlate with MT1 expression
The relationship between MT1 expression and invasive capacity of
ovarian cancer cell lines was assessed using a transwell collagen
invasion assay. HEY cells had extensively penetrated the collagen I
barrier by 24h (Figure 2A). In comparison, OVCA429 and ES-2
cells required twice as long to accomplish moderate levels of
invasion, whereas HOC-7 cells rarely invaded. SKOV-3 and
OVCAR-3 cells, which do not express MT1, did not invade, even
when incubated for up to 5 days (data not shown). Invasion was
abolished (495%) by the presence of GM6001 in the culture
medium (Figure 2A), with similar effects obtained when OVCA429
and ES-2 cells were used (data not shown). These studies
demonstrate an essential role of MMP-mediated proteolysis for
invasion of these collagen I matrices.
To examine the relationship between transwell collagen invasion
and matrix degradation, the ability of cells to clear the collagen
plugs within pores of collagen-coated transwell membranes was
assessed. Only those cell lines expressing MT1 removed collagen
from the transwell pores (Figure 2B), consistent with the transwell
invasion results. HEY cells showed extensive clearing of collagen
from the pores by 24h, whereas OVCA429, ES-2, and HOC-7 cells
required a longer incubation to accomplish collagen degradation.
By 55h, HEY cells had cleared essentially all pores, OVCA429 cells
had cleared 40–50% of pores and ES-2 and HOC-7 cells had
cleared only 10–20% of pores. In contrast, SKOV-3 and OVCAR3
cells were unable to clear the pores. Incubation of HEY cells with
GM6001 prevented collagen clearing (Figure 2B), with similar
results obtained for OVCA429 and ES-2 cells.
Cell lines expressing endogenous MT1 generally show
higher motility on collagen I
As MT1 promotes the motility of several cancer cell types on
various matrices including collagen (Gingras et al, 2001; Rozanov
et al, 2001; Takino et al, 2004), we evaluated this potential
association within our panel of ovarian cancer cell lines. For these
experiments, we assessed the ability of the cells to transverse
transwell membranes coated with collagen I that was left
unpolymerised, to eliminate the prerequisite of proteolysis.
SKOV-3 and OVCAR-3 cells were significantly less motile than
the MT1-expressing cell lines. However, within the MT1-expres-
sing cell lines, there was not a clear correlation between the level of
MT1 expression and motility. HEY cells, which express the highest
levels of MT1, exhibited the same level of motility as OVCA429 and
ES-2 cells, which express much lower levels of MT1 (Figure 2C).
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Figure 2 Collagen I transwell invasion, matrix degradation and motility of
ovarian cancer cell lines. (A) Collagen I transwell invasion capacity. Results
from three independent experiments were normalised to HEY and data
were pooled. Bars represent the mean7s.e. (nd – HEY invasion was not
assessed beyond 24h as invasion was complete by this time). (B)
Clearance/degradation of collagen I plugs from transwell invasion
membranes. Confocal fluorescence microscopy was used ( 16) to
visualise the biotinylated collagen. Representative areas near the centre of
the membrane are shown and arrows highlight transwell pores that have
been cleared of their collagen I plugs, except for HEY, in which all pores
were cleared. Inset shows an enlarged image that distinguishes cleared
pores (black) from uncleared pores (grey). (C) Transwell migration through
unpolymerised collagen I-coated transwells at 8–10h. Results from three
independent experiments were normalised to HEY and data were pooled.
Bars represent the mean7s.e.
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The contribution of MT1 to invasion was assessed using a variety
of MMP inhibitors. HEY cells were chosen for these experiments,
as they consistently exhibited the most invasive behaviour.
Invasion was abolished by the broad-range MMP inhibitor
GM6001, indicating the essential role of MMP-mediated proteo-
lysis in this process (Figure 3A). Tissue inhibitor of metallopro-
teinase-1, which does not affect MT1 activity (Will et al, 1996), but
is an effective inhibitor of all secreted MMPs (Hornebeck et al,
2005), did not affect invasion. Although the selective inhibition of
the gelatinases, MMP-2 and MMP-9 with SB-3CT (Kleifeld et al,
2001) resulted in a 20% reduction in invasion, this decrease was
modest in comparison to the reduction attained with TIMP-2,
which prevented invasion as effectively as GM6001 (490%
inhibition). In contrast to SB-3CT and TIMP-1, GM6001 and
TIMP-2 are potent inhibitors of MT1 (Will et al, 1996).
Collectively, these results indicate a critical requirement of MT1,
and not other MMPs, for collagen I invasion.
Membrane-type 1 expression activates invasive behaviour
by non-invasive cells
As our experiments indicated that inhibition of MT1 activity
prevented invasive behaviour, we next examined whether MT1 was
a limiting factor for ovarian cancer cell invasion. Both the non-
invasive SKOV-3 and OVCAR-3 cells and the moderately invasive
OVCA429 and ES-2 cell lines were transfected with either wild-type
MT1 (MT1f) or catalytically inactive MT1 (E24A) expression
constructs, and subjected to a transwell invasion assay. Compar-
able and high levels of expression were achieved with both
constructs, at levels vastly exceeding endogenous MT1 expression
by the invasive OVCA429 and ES-2 cell lines (Figure 3C).
Transfection efficiency exceeded 50% for each of the four cell
lines transfected, as shown using EGFP expression (Figure 3D).
Membrane-type 1 overexpression by the moderately invasive
OVCA429 and ES-2 cells caused a marked acceleration in their
invasion. Moreover, ectopic expression of MT1 in the non-invasive
SKOV-3 and OVCAR-3 cell lines activated an invasive phenotype
(Figure 3B). Although MT1 overexpression allowed all cell lines to
penetrate the collagen barrier within 24h, the extent of invasion
was correlated with motility. As SKOV-3 and OVCAR-3 cells were
less motile, a longer incubation (48h) was required to achieve
extensive invasion by the MT1-transfected cells (Figure 3B). In
contrast to MT1, overexpression of the E240A mutant was without
effect, indicating the requirement for MT1 catalytic activity in the
enhanced invasion.
Membrane-type 1 promotes invasion solely through
enhanced matrix degradation and not cell motility
Cell invasion can be partitioned into matrix degradation and cell
motility. As MT1 has been implicated in both, we examined the
impact of its overexpression on these processes independently to
determine the mechanism through which MT1 promoted invasion.
SKOV-3 and OVCAR-3 cells were transfected as described in the
previous experiment. To assess matrix degradation, cells were
seeded in chamber slides pre-coated with polymerised collagen
that was biotinylated to allow visualisation. After 24h, cells and
matrices were fixed and analysed by confocal microscopy.
Overexpression of MT1 resulted in a striking enhancement of
collagen degradation, as shown by the cleared areas in Figure 4A.
In comparison, non-transfected cells, and cells transfected with
E240A, did not exhibit collagen clearance. Similar results were
obtained when OVCA429 and ES-2 cells were transfected with
these constructs (data not shown).
To determine whether MT1 also promoted the migration of
ovarian cancer cells, as demonstrated in other cancer cell types
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Figure 3 A critical role for MT1 in collagen I invasion by ovarian cancer
cells. (A) Selective inhibition of MT1 blocks invasion. HEY cells were
incubated with the indicated inhibitors during a 24h invasion assay. Data
were analysed by one-way ANOVA followed by Student–Newman–Keuls
multiple comparison test. Bars with different letters are statistically different
from one another. (B) Expression of catalytically active MT1 is sufficient to
cause invasion by the non-invasive SKOV-3 and OVCAR-3 cells, and also
markedly enhances invasion by the moderately invasive OVCA429 and ES-
2 cells. In contrast, expression of the MT1 catalytically inactive mutant,
E240A, had no effect on invasion compared with the GFP-transfected
control. (C) Verification of MT1 and E240A expression by transfected cells.
RT–PCR for MT1 shows comparable expression of the MT1f (M) and the
E240A mutant (E) were achieved, both of which were expressed far in
excess of endogenous (U) MT1 levels of OVCA429 and ES2. (D) The
transfection efficiency exceeded 50% for all cell lines, shown using
fluorescence microscopy of the GFP-transfected control cells. The upper
panel shows GFP fluorescence indicating transfected cells, whereas the
lower panel shows all cells in the field by light microscopy.
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s(Gingras et al, 2001; Rozanov et al, 2001; Cao et al, 2004; Takino
et al, 2004), the transfected cells were subjected to a transwell
collagen migration assay. In contrast to its striking effect on
collagen degradation, MT1 expression did not enhance cell
migration (Figure 4B). Consistent with these observations,
treatment of the MT1-expressing cells (HEY, 429, and ES-2) with
GM6001 did not alter their motility (data not shown). Together,
these data demonstrate that ovarian cancer cell motility is not
promoted by MT1 proteolytic activity or expression.
Invasive capacity does not relate to E-cadherin expression
E-cadherin is considered to be a tumour suppressor, as its
expression is associated with increased cell–cell adhesion and
decreased motility. The inability of SKOV-3 and OVCAR-3 cells to
invade 3-D collagen gels may relate to their E-cadherin expression
(Kokenyesi et al, 2003). That MT1 expression is upregulated
through b-catenin signalling may explain the reported inverse
correlation between E-cadherin and MT1 expression (Ara et al,
2000; Takahashi et al, 2002; Nawrocki-Raby et al, 2003a,b; Hazan
et al, 2004; Hlubek et al, 2004; Munshi and Stack, 2006). Therefore,
we analysed cadherin expression to determine whether E-cadherin
was associated with the absence of MT1 and cell invasion in SKOV-
3 and OVCAR-3 cells. The expression of N-cadherin was also
assessed, as this cadherin sub-type has been associated with motile
carcinoma cells that have undergone epithelial-mesenchymal
transition (Derycke and Bracke, 2004; Hazan et al, 2004).
Both RT–PCR and Western blot analysis of cell lysates revealed
that E-cadherin expression was restricted to HOC-7 cells, whereas
the other five cell lines expressed N-cadherin (Figure 5A). These
findings demonstrate that E-cadherin expression is not a factor
contributing to the inability of the SKOV-3 and OVCAR-3 cell lines
to invade and migrate on collagen. However, E-cadherin expres-
sion may explain the lower motility and invasiveness of the
MT1-expressing HOC-7 cells relative to the other invasive MT1-
expressing cells.
DISCUSSION
Our results establish a critical role for MT1 in ovarian cancer cell
invasion and are the first to reveal its expression in a panel of
cancer cell lines exhibiting different capacities for invasion.
Endogenous MT1 expression and activity were positively corre-
lated with invasiveness in the six ovarian cancer cell lines
examined. Importantly, the levels of invasion indicated by our in
vitro assays mirrored the reported abilities of the cell lines to form
peritoneal tumours in vivo (Shaw et al, 2004). HEY, OVCA429, and
ES-2 cell lines expressed the highest levels of MT1, and were
consistently shown to be the most invasive in the in vitro assays
used. These three cell lines also reproducibly formed invasive
intraperitoneal tumours in mice (Shaw et al, 2004). Conversely, we
found SKOV-3 and OVCAR-3 cells did not express MT1 and were
incapable of invading polymerised collagen I matrices in vitro.
Consistent with these results, SKOV-3 and OVCAR-3 seldom
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Figure 5 Expression of E- and N-cadherin by ovarian cancer cell lines.
(A) RT–PCR for E-cadherin. RPL13a amplification verified equal amounts
of cDNA template. (B) Western blot analysis for E- and N-cadherin. Blots
were reprobed with b-tubulin to verify equal loading.
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Figure 4 MT1 enhances invasion solely through its promotion of matrix
degradation; not by affecting cell motility. (A) Degradation of biotinylated
collagen I matrices by MT1-transfected SKOV-3 and OVCAR-3 cells after a
24h incubation. Matrices were not degraded by cells expressing the E240A
catalytically inactive MT1 mutant, nor by control untransfected (UT) cells.
Cells were visualised via rhodamine phalloidin staining of actin (red) and
biotinylated collagen matrices were visualised using streptavidin AF488
(green), using confocal microscopy ( 40). (B) Overexpression of MT1 or
E240A did not affect cell motility on collagen. Cells were seeded in
transwell chambers pre-coated with 20mg unpolymerised collagen and
allowed to migrate for 8–10h. Results shown are the mean7s.e. for three
independent experiments.
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sformed intraperitoneal tumours (Shaw et al, 2004). HOC-7 cells,
which express moderate levels of MT1 (but have not been assessed
for tumour-forming ability in vivo), did not invade efficiently in
our assays, despite having a moderate capacity to degrade the
collagen I plugs within transwells.
Collagen I was selected for use in these studies as it is a principal
component of the peritoneal stromal matrix, to which invading
cancer cells adhere in vivo (Moser et al, 1996; Ghosh et al, 2002;
Mochizuki et al, 2004). Further, matrices composed of collagen I
stimulated the most rapid/extensive dissemination of ovarian
cancer cells from spheroids (Burleson et al, 2004). Although
Matrigelt has been commonly used for invasion assays, its
suitability for this purpose has recently been challenged (Hotary
et al, 2006). This EHS sarcoma extract contains basement
membrane components that reconstitute into a loose matrix
stabilised predominantly by non-covalent interactions, but in
critical contrast to native basement membranes, MMP activity is
not required for cell penetration (Even-Ram and Yamada, 2005;
Hotary et al, 2006). We have verified that ovarian cancer cell
penetration of this synthetic matrix is independent of MMPs as
evidenced by a failure of GM6001 to block cell penetration (data
not shown). For this reason, Matrigelt matrices were not utilised
in this study.
We have established MT1 to be the prime determinant of
ovarian cancer cell invasion both by inhibiting MT1 activity in
invasive cells, and by expressing it in the non-invasive cell lines
that lack its expression. As MT1-specific inhibitors have yet to be
developed, and we were unable to downregulate MT1 with siRNA
in these cell lines, we used the widely accepted approach of
employing MMP inhibitors with differing target specificity to
enable a subtractive deduction of MT1-specific activity (Nakamura
et al, 2004; Nisato et al, 2005; Egawa et al, 2006). Invasion was
unaffected by TIMP-1, which inhibits all soluble (non-transmem-
brane) MMPs without inhibiting MT1 (Hornebeck et al, 2005). In
contrast, invasion was abolished by GM6001 and TIMP-2, both of
which include MT1 in their inhibitory spectra (Will et al, 1996).
Matrix metalloproteinase-2 is activated by MT1 in a TIMP-2
dependent manner (Strongin et al, 1995) and cooperates with
MT1 in collagen clearance by further degrading denatured 3/4-
and 1/4-cleaved collagen fragments generated by the collagenase
activity of MT1 (Tam et al, 2002). Our results indicate
that gelatinolytic activities of MMP-2 or MMP-9 are not required
for collagen I invasion by ovarian cancer cells as treatment
with the MMP-2/MMP-9 inhibitor SB-3CT caused only a small
reduction in invasion. Thus, the critical role of MT1 does
not involve its activation of pro-MMP-2. Rather, our findings
suggest the direct cleavage of collagen I by MT1 as the
critical activity necessary for invasion of this matrix. A similar
dependence on MT1 and not MMP-2 has been recently reported
for endothelial cell collagen I invasion (Nisato et al, 2005) and for
in vitro invasion of an authentic basement membrane matrix
(Hotary et al, 2006).
Further evidence that MT1 has a pivotal role in collagen
invasion is provided by our MT1 transfection studies. Ectopic MT1
expression permitted the non-MT1-expressing SKOV-3 and
OVCAR-3 cell lines to invade collagen I and markedly enhanced
the invasive abilities of OVCA429 and ES-2 cells, which had
moderate endogenous MT1 expression. This effect of MT1
required the presence of the active catalytic domain.
Clustering of the collagen binding integrins has been implicated
in the cell surface localisation, and thus activity of MT1. The
collagen I-stimulated translocation of MT1 to the cell membrane
has been suggested as a rate-limiting event for pro-MMP-2
activation and invasion by DOV-13 cells (Ellerbroek et al, 2001).
Interestingly, MT1 activity levels in our cells, as determined by
pro-MMP-2 cleavage, and collagen I degradation generally
reflected the constitutive levels of MT1 mRNA and protein,
suggesting that potential variations in events required for MT1
surface translocation (activation) were not a major influencing
factor among the cell lines examined.
It is important to note that other groups have reported
endogenous MT1 expression in SKOV-3 and OVCAR-3 cells as
determined by Western blot analysis. We have often observed
numerous nonspecific bands migrating near the MT1 band with
different commercial antibodies, including some lots of Ab815, in
extracts from breast and ovarian cancer cells. For this reason, we
validated MT1 expression by real-time RT–PCR using RNA
extracts derived on three separate occasions, and by gelatin
zymography to show pro-MMP-2 activation consistent with MT1
expression. Moreover, recent proteomic studies with these cell
lines support our present results (manuscript in preparation). It is
possible that differences in MT-1 expression may reflect changes in
cell characteristics emerging over time in different laboratories;
however, we feel it is best to support results from Western blot
analysis for MT1 by additional means. Nevertheless, our studies
clearly show the causal relationship between MT1 expression and
invasive behaviour within the panel of six ovarian cancer cell lines
used in this study.
Our initial observation that the MT1-expressing cell lines were
overall more motile on a non-polymerised collagen I matrix raised
the possibility that MT1 could contribute to invasion by enhancing
motility as well as collagen degradation. Several studies have
reported motility to be somewhat enhanced by overexpression of
wild-type MT1 (Gingras et al, 2001; Rozanov et al, 2001; Cao et al,
2004; Takino et al, 2004). MT1 effects on cell motility may be
exerted through integrin activation, as MT1-mediated cleavage of
the vitronectin receptor avb3 enhanced breast cancer cell motility
on this substrate (Deryugina et al, 2002). Although avb3 integrin is
a receptor for fibronectin rather than collagen, it has been reported
to be essential for endothelial cell invasion of a collagen I matrix;
its participation perhaps relates to a coating of the collagen I with
fibronectin or vitronectin from the serum-containing culture
media or from the cells themselves, and may play a general role
in cell motility on collagen I matrices (Nisato et al, 2005). The
mechanism through which MT1 overexpression stimulated the
enhanced cell motility is unclear, as controversial reports exist
regarding the requirement of its catalytic activity (Gingras et al,
2001; Rozanov et al, 2001; Takino et al, 2004; cf. Cao et al, 2004).
Further, an inverse relationship between matrix clearance and
MT1-mediated integrin activation create a complex dual effect on
motility (Deryugina et al, 2003). Importantly, all studies that have
reported MT1 overexpression to enhance motility were conducted
in cell types other than ovarian cancer cells. Our MT1 over-
expression and GM6001 studies indicate that MT1 expression does
not enhance ovarian cancer cell motility on collagen I and are
consistent with the report that GM6001 had no effect on the
motility of DOV13 ovarian cancer cells on this matrix (Ellerbroek
et al, 2001). Thus, although the cell lines that express endogenous
MT1 are more motile than those that lack MT1 expression, this
relationship is correlative and not causal; MT1 does not appear to
contribute to their superior motility. Rather, MT1 is likely
regulated in parallel with the pathways that promote a motile
phenotype.
Although cell motility was not altered by manipulation of
MT1 expression or activity, migratory capacity is an important
factor in determining the extent of invasion. The importance of
migratory capacity in ovarian cancer metastasis is perhaps
best illustrated by the fact that therapeutic strategies aimed
at preventing tumour cell motility reduce peritoneal metastasis
of ovarian cancer cells (Hashimoto et al, 2005). Motility and
invasion of numerous cancer cell types is prevented by expression
of the tumour-suppressor E-cadherin. Through its sequestration
of the transcriptional co-activator b-catenin, E-cadherin inhibits
Tcf/LEF transcriptional activation of numerous targets that
contribute to a motile, invasive phenotype, including MT1
(Ara et al, 2000; Takahashi et al, 2002; Nawrocki-Raby et al,
MT1 promotes ovarian cancer cell invasion
KL Sodek et al
364
British Journal of Cancer (2007) 97(3), 358–367 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s2003a,b; Hazan et al, 2004; Hlubek et al, 2004; Munshi and Stack,
2006).
The pattern of E-cadherin expression in ovarian cancer appears
to be distinct from that of most other epithelial cancers. Primary
ovarian carcinomas have upregulated E-cadherin and are more
epithelial in character than the N-cadherin-expressing ovarian
surface epithelium (mesothelium) from which they are presumed
to arise. Subsequently, E-cadherin expression decreases and
correlates with progression to metastatic disease, in a manner
similar to other carcinomas (Auersperg et al, 2002; Yuecheng et al,
2006) indicating ovarian cancer metastasis is likely promoted by
the de-differentiation that accompanies E-cadherin downregula-
tion. It has been suggested that the inability of the SKOV-3 and
OVCAR-3 ovarian cancer cell lines to invade collagen I may be due
to their E-cadherin expression (Kokenyesi et al, 2003). However,
our studies clearly show that of the cells used in the present study,
only HOC-7 expressed E-cadherin, whereas the other cell lines
expressed N-cadherin. The idea proposed by Kokenyesi et al,
(2003) is consistent with the behaviour of the HOC-7 cells, which
have an epithelial morphology, grow in tight clusters, and migrate
as a sheet in wound-healing assays (K Sodek, unpublished
observations), indicative of the strong cell–cell adhesion endowed
by their E-cadherin expression. Migration of cells through a
collagen I gel, as in the Kokenyesi study, or through the narrow
8mm diameter transwell pores, as used in the current study, would
require cell–cell detachment, and would thus likely be impeded by
E-cadherin expression.
Expression of MT1 by cancer cells in ovarian tumours has been
associated with poor patient survival (Davidson et al, 1999; Sakata
et al, 2000; Davidson et al, 2002). As with other cancers, MMP
inhibitors have yielded disappointing results in ovarian cancer
clinical trials, likely because they have been administered at late
stages of disease and are broad-range, inhibiting MMPs that have
anti-tumorigenic/anti-angiogenic activities (Overall and Lopez-
Otin, 2002). Alternatively, it has been recently reported that the
inhibitor concentrations required to inhibit MMP catalytic activity
are far above the physiological levels achieved (Hotary et al, 2006).
Furthermore, the MMP inhibitors marimastat and tanomastat,
which have been administered in ovarian cancer trials, are
selective for MMPs other than MT1 (Hidalgo and Eckhardt,
2001). The development of specific inhibitors of MT1 has proven a
difficult task, as its structure is similar to other MMPs yet, more
restrictive, thus inhibitors that bind MT1 also tend to bind other
MMPs, especially the gelatinases (Yamamoto et al, 1998). However,
the further development of a new class of peptidomimetic
mercaptosulphide MMP inhibitors that have high selectivity for
MT1 and the gelatinases holds promise for design of a specific
MT1 inhibitor (Hurst et al, 2005; Fisher and Mobashery, 2006). An
additional attractive approach is to establish and target the
pathways that govern MT1 expression.
As cell motility is clearly related to the extent of invasion of
ovarian cancer cells, it is important to determine factors
synchronising this aspect of invasive behaviour with matrix
degradation. The combination of gene expression profiling,
proteomics and bioinformatical approaches as applied to
these cell lines are necessary to better understand potential
pathways through which MT1 expression and cell motility are
regulated, and are likely to reveal new therapeutic targets for
ovarian cancer.
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